MABE1031
Anti-poly-ADP-ribose binding reagent
Anti-poly-ADP-ribose binding reagent is a reagent that selectively binds to ADP ribose for use in Western Blotting, Immunocytochemistry and Dot Blot.
Synonym(s):
poly-ADP-ribose binding reagent
Select a Size
About This Item
biological source
Escherichia coli
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
species reactivity
human, mouse
species reactivity (predicted by homology)
all
technique(s)
dot blot: suitable
immunocytochemistry: suitable
western blot: suitable
shipped in
dry ice
target post-translational modification
unmodified
General description
Application
Immunocytochemistry Analysis: A representative lot detected oligo(ADPR) and poly(ADPR)/PAR in 3T3-L1 cells (Lee Kraus, University of Texas Southwestern Medical Center).
Epigenetics & Nuclear Function
General Post-translation Modification
Biochem/physiol Actions
Physical form
Preparation Note
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -80°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Analysis Note
Western Blotting Analysis: This reagent detected oligo(ADPR) and poly(ADPR) on ADP-ribosylated PARP1 recombinant protein (Lee Kraus, University of Texas Southwestern Medical Center).
Other Notes
Disclaimer
Not finding the right product?
Try our Product Selector Tool.
Storage Class
12 - Non Combustible Liquids
wgk_germany
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
A major focus of breast cancer research is to understand the mechanisms responsible for disease progression and drug resistance. Toward that end, it has been found that approximately two thirds of all human breast carcinomas overexpress the Estrogen Receptor α (ERα) protein and it remains the primary pharmacological target for endocrine therapy1,2. The normal cellular function of ERα is as a transcription factor that mediates a wide variety of physiological processes, many of which are dependent upon phosphorylation of the receptor at specific amino acid residues3,4. Indeed, ERα is known to be phosphorylated at a multitude of different sites, yet how these all correlate to disease remains unclear5. Here, we interrogated multiple sites of ERα for phosphorylation status by screening an extensive panel of different breast cancer patient samples and other non-breast cancer tissue microarray (TMA) slide samples to determine their relevance to disease.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service